Cargando…

358. Comparison of Voriconazole (VORI), Isavuconazole (ISAV), and Posaconazole (POSA) in the Initial Treatment of Patients With Invasive Aspergillosis (IA)

BACKGROUND: While VORI is recommend as first-line therapy for patients with IA, ISAV, and POSA have been approved for the treatment and prophylaxis of IA, respectively. We evaluated treatment responses among patients with IA receiving triazole antifungals. METHODS: We performed a retrospective cohor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Matthew P, Orejas, José Luis, Arbona-Haddad, Esther, Marty, Francisco M, Koo, Sophia, Hammond, Sarah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255647/ http://dx.doi.org/10.1093/ofid/ofy210.369

Ejemplares similares

Aldeanos de Vory /
por: Leonov, Leonid, 1899-1994
Publicado: (1928)

Posaconazole and isavuconazole induced hypomagnesaemia
por: Burston, John, et al.
Publicado: (2018)

Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis-review of the literature
por: Sandherr, M, et al.
Publicado: (2011)

Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011)

Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis
por: Harrington, Rachel, et al.
Publicado: (2016)

Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden
por: Floros, Lefteris, et al.
Publicado: (2019)

Posaconazole achieves prompt recovery of voriconazole-induced liver injury in a case of invasive aspergillosis
por: Martínez-Casanova, Javier, et al.
Publicado: (2018)

Comparison of clinical pharmacology of voriconazole and posaconazole
por: Sienkiewicz, Beata M., et al.
Publicado: (2016)

Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial
por: Vanderbeke, Lore, et al.
Publicado: (2021)

Pharmacokinetic and Exposure Response Analysis of the Double-Blind Randomized Study of Posaconazole and Voriconazole for Treatment of Invasive Aspergillosis
por: Maertens, Johan A., et al.
Publicado: (2023)

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials
por: Andes, David R., et al.
Publicado: (2018)

411. Tolerability of Isavuconazole After Posaconazole Toxicity in Leukemia Patients
por: DiPippo, Adam J, et al.
Publicado: (2018)

1169. In Vitro Activity of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults Enrolled in a Clinical Trial
por: Castanheira, Mariana, et al.
Publicado: (2020)

Exposure of Cryptococcus neoformans to Seven Commonly Used Agricultural Azole Fungicides Induces Resistance to Fluconazole as Well as Cross-Resistance to Voriconazole, Posaconazole, Itraconazole and Isavuconazole
por: Drakulovski, Pascal, et al.
Publicado: (2023)

Antibacterials/isavuconazole/voriconazole: Lack of efficacy: case report
Publicado: (2020)

The Effect of Posaconazole and Isavuconazole on the Pharmacokinetics of Erdafitinib in Beagle Dogs by UPLC-MS/MS
por: Ruan, Lan-hong, et al.
Publicado: (2021)

610. Voriconazole versus isavuconazole in patients with invasive aspergillosis: a retrospective study in a medically insured population across the United States
por: Chan, Sophea, et al.
Publicado: (2023)

2731. Posa-bly the Better Option? Comparison of Posaconazole vs. Itraconazole for Antifungal Prophylaxis After Heart Transplantation
por: Drucker, Darra, et al.
Publicado: (2023)

Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study
por: Yi, Whitley M., et al.
Publicado: (2017)

Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections
por: Donnelley, Monica A, et al.
Publicado: (2016)

Voriconazole-refractory invasive aspergillosis
por: Park, Se Yoon, et al.
Publicado: (2017)

Treatment of Disseminated Aspergillosis with Posaconazole in 10 Dogs
por: Corrigan, V.K., et al.
Publicado: (2016)

Amphotericin-B-liposomal/isavuconazole/voriconazole: Lack of efficacy: 6 case report
Publicado: (2022)

Isavuconazole/piperacillin/tazobactam/voriconazole: Drug-induced liver injury: case report
Publicado: (2022)

The Effect of Posaconazole, Itraconazole and Voriconazole in the Culture Medium on Aspergillus fumigatus Triazole Resistance
por: Mroczyńska, Martyna, et al.
Publicado: (2020)

Orbital Aspergillosis: Voriconazole – The New Standard Treatment?
por: Ohlstein, Derek H., et al.
Publicado: (2012)

2121. Isavuconazole (ISAV) as Primary Anti-Fungal Prophylaxis (PAP) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): An Open-Label, Prospective Study
por: Bose, Prithviraj, et al.
Publicado: (2019)

Antifungal prophylactic effectiveness and intrapulmonary concentrations of voriconazole versus posaconazole in lung transplant recipients
por: Ju, Chunrong, et al.
Publicado: (2022)

Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia
por: Tu, Songji, et al.
Publicado: (2023)

Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations
por: Li, Julius, et al.
Publicado: (2015)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

Therapeutic Drug Monitoring of Sputum Voriconazole in Pulmonary Aspergillosis
por: Sarfati, Sacha, et al.
Publicado: (2022)

P059 The overexpression of efflux pump gene cdr1B resulting in voriconazole- and isavuconazole- resistance in Aspergillus fumigatus recovered from a patient with chronic pulmonary aspergillosis in China
por: Liang, Tianyu, et al.
Publicado: (2022)

Infectious salmon anaemia virus (ISAV) in Chilean Atlantic salmon (Salmo salar) aquaculture: emergence of low pathogenic ISAV-HPR0 and re-emergence of virulent ISAV-HPR∆: HPR3 and HPR14
por: Godoy, Marcos G, et al.
Publicado: (2013)

1291. Safety of Isavuconazole Compared with Voriconazole as Primary Antifungal Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients
por: Bogler, Yael, et al.
Publicado: (2020)

Therapeutic Drug Monitoring of Isavuconazole: Serum Concentration Variability and Success Rates for Reaching Target in Comparison with Voriconazole
por: Risum, Malene, et al.
Publicado: (2021)

Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial
por: Perfect, John R., et al.
Publicado: (2018)

Posaconazole or isavuconazole as sole or predominant antifungal therapy for COVID-19-associated mucormycosis. A retrospective observational case series
por: Soman, Rajeev, et al.
Publicado: (2022)

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi
por: Desai, Amit V., et al.
Publicado: (2017)

Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy
por: Jenks, Jeffrey D, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_s5i579i0tdphe3v0vcfp6ogfah